A new computational drug repurposing method using established disease-drug pair knowledge

MOTIVATION Drug repurposing is a potential alternative to the classical drug discovery pipeline. Repurposing involves finding novel indications for already approved drugs. In this work, we present a novel machine learning-based method for drug repurposing. This method explores the anti-similarity between drugs and a disease to uncover new uses for the drugs. More specifically, our proposed method takes into account three sources of information: i) large scale gene expression profiles corresponding to human cell lines treated with small molecules, ii) gene expression profile of a human disease and iii) the known relationship between FDA-approved drugs and diseases. Using these data, our proposed method learns a similarity metric through a supervised machine learning-based algorithm such that a disease and its associated FDA-approved drugs have smaller distance than the other disease-drug pairs. RESULTS We validated our framework by showing that the proposed method incorporating distance metric learning technique can retrieve FDA-approved drugs for their approved indications. Once validated, we used our approach to identify a few strong candidates for repurposing. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  Zuping Zhang,et al.  Network-Based Inference Methods for Drug Repositioning , 2015, Comput. Math. Methods Medicine.

[2]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[3]  Elisabeth Petit-Teixeira,et al.  Transcriptome Analysis Describing New Immunity and Defense Genes in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis Patients , 2009, PloS one.

[4]  Jeffrey A Whitsett,et al.  EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[5]  Nasser Ghadiri,et al.  A review of network‐based approaches to drug repositioning , 2018, Briefings Bioinform..

[6]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[7]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[8]  E. Grace,et al.  Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness. , 1986, Current medical research and opinion.

[9]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[10]  Werner E. Siebert,et al.  Lasers in the Musculoskeletal System , 2001, Springer Berlin Heidelberg.

[11]  M. Delorenzi,et al.  Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer , 2011, PloS one.

[12]  Ivana V. Yang,et al.  The Peripheral Blood Transcriptome Identifies the Presence and Extent of Disease in Idiopathic Pulmonary Fibrosis , 2012, PloS one.

[13]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[14]  Barry D Kahan,et al.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.

[15]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[16]  Lin Lu,et al.  Machine Learning and Network Methods for Biology and Medicine , 2015, Comput. Math. Methods Medicine.

[17]  Gereon Hüttmann,et al.  Experimental Photodynamic Laser Therapy for Rheumatoid Arthritis Using Photosan-3, 5-ALA-Induced PPIX and BPD Verteporfin in an Animal Model , 2001 .

[18]  S T Roweis,et al.  Nonlinear dimensionality reduction by locally linear embedding. , 2000, Science.

[19]  Sorin Drăghici,et al.  Statistics and Data Analysis for Microarrays Using R and Bioconductor , 2016 .

[20]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[21]  L. Xu,et al.  Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation , 2013, Cell Death and Disease.

[22]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[23]  Emre Guney,et al.  A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection , 2018, npj Systems Biology and Applications.

[24]  Yan Zhao,et al.  Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.

[25]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[26]  H. Lehrach,et al.  Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. , 2010, Physiological genomics.

[27]  Salvatore Alaimo,et al.  Drug–target interaction prediction through domain-tuned network-based inference , 2013, Bioinform..

[28]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[29]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[30]  Salvatore Alaimo,et al.  Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning. , 2016, Methods in molecular biology.

[31]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[32]  Natalia Novac,et al.  Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.

[33]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[34]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[35]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[36]  Xiuzhen Han,et al.  The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.

[37]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[38]  Jaana Kekäläinen,et al.  Cumulated gain-based evaluation of IR techniques , 2002, TOIS.

[39]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[40]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[41]  Zora Modrusan,et al.  Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis , 2014, Thorax.

[42]  P. Mahalanobis On the generalized distance in statistics , 1936 .

[43]  J. Holden,et al.  Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. , 1997, Human pathology.

[44]  Peng Sun,et al.  Drug repurposing by integrated literature mining and drug-gene-disease triangulation. , 2017, Drug discovery today.

[45]  Z. Szallasi,et al.  Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. , 2004, Nucleic acids research.

[46]  M. Dickson,et al.  The cost of new drug discovery and development. , 2004, Discovery medicine.

[47]  E. Tobinick The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[48]  F. Klamt,et al.  Alzheimer’s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates , 2018, Alzheimer's Research & Therapy.

[49]  Erika Melissari,et al.  Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays , 2010, Experimental biology and medicine.

[50]  Takeshi Fukuda,et al.  Gefitinib prevents bleomycin-induced lung fibrosis in mice. , 2006, American journal of respiratory and critical care medicine.

[51]  Georg Schett,et al.  Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[52]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2004, Nucleic Acids Res..

[53]  B. Munos Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[54]  I. Jolliffe Principal Component Analysis , 2002 .

[55]  Francesmary Modugno,et al.  A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis , 2003, Breast Cancer Research and Treatment.

[56]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[57]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[58]  A. Barabasi,et al.  Network-based in silico drug efficacy screening , 2016, Nature Communications.

[59]  T. Libermann,et al.  Testing New Drugs for Treatment of Melanoma Patients Applying Connectivity Map Database Analysis with Melanoma Gene Signatures , 2012 .

[60]  Robert D Davis,et al.  Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle , 2011, BMC Medical Genomics.

[61]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.